By Jason Chau
Shares of Hong Kong-listed InSilico Medicine jumped after the drugmaker said it has administered first doses of its new treatment for inflammatory bowel disease to patients.
The stock surged about 18% on Monday to 55.2 Hong Kong dollars, after the biotech firm said it completed the first patient first dose of Garutadustat. The drug is a treatment for inflammatory bowel disease therapy currently under Phase IIa clinical trials which was discovered and developed by InSilico's generative AI platform Pharma.AI.
Inflammatory bowel disease, most notably ulcerative colitis, involves the recurring inflammation of the gastrointestinal tract and affects millions globally.
"Given the encouraging results from our Phase I studies on Garutadustat's safety and gut-restricted profile, we look forward to seeing how these benefits will be translated into ulcerative colitis patient population," Carol Satler, MD, PhD, a senior vice president at InSilico said in an exchange filing.
The Cambridge, Massachusetts based company said it is focused on integrating AI into the drug discovery process and its AI model can be used in other industries as well, including agriculture and advanced materials.
Its shares started trading in Hong Kong on Dec. 30 last year after raising HK$2.28 billion, equivalent to US$292.6 million, in its initial public offering. Its recent IPO attracted a list of high profile investors including U.S. pharma major Eli Lilly, Tencent and Temasek Holdings.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
January 12, 2026 00:34 ET (05:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments